Guangdong Kangping Pharmaceutical Innovation Technology Development

Guangdong Kangping Pharmaceutical Innovation Technology Development is a Chinese pharmaceutical company focused on the research, development, and commercialization of innovative small molecule drugs. The company is best known for its development of Ilaprazole, a next-generation proton pump inhibitor (PPI) used for the treatment of acid-related gastrointestinal disorders such as gastric ulcers and reflux esophagitis. While the drug was licensed to Livzon Pharmaceutical Group for commercialization in China, Kangping remains a key entity in the innovation landscape of the region. The company operates primarily out of Guangzhou, leveraging local R&D infrastructure to advance its therapeutic pipeline.